The following table summarizes restructuring, acquisition, and related costs in the accompanying consolidated statements of operations (in thousands):


	Three Months Ended
	March 28,			March 29,
	2025			2024
2024 restructuring	$	590		$	548
2020 restructuring		(3,595	)		—
Total restructuring charges		(3,005	)		548
Acquisition and related charges		550			1,735
Total restructuring, acquisition, and related costs	$	(2,455	)	$	2,283

As a result of the Company’s acquisitions and ongoing integration activities, the Company initiated the 2024 restructuring program in the first quarter of 2024 in order to reduce operating complexity. During the three months ended March 28, 2025, the Company recorded $0.6 million in severance, facility related and other charges in connection with the 2024 restructuring program. As of March 28, 2025, the Company had incurred cumulative costs of $11.1 million related to this restructuring program. The Company anticipates substantially completing the 2024 restructuring program by the end of 2025 and expects to incur additional restructuring charges of $5.0 million to $6.0 million related to the 2024 restructuring program.

The following table summarizes restructuring costs associated with the 2024 restructuring program by reportable segment (in thousands):


	Three Months Ended
	March 28,		March 29,
	2025		2024
Automation Enabling Technologies	$	486	$	279
Medical Solutions		82		206
Unallocated		22		63
Total	$	590	$	548

As a result of the Company’s ongoing evaluations and efforts to reduce its operating costs, while improving efficiency and effectiveness, the Company initiated the 2020 restructuring program in the third quarter of 2020. This program was focused on reducing operating complexity in the Company, including reducing infrastructure costs and streamlining the Company’s operating model to better serve its customers. In addition, the program was focused on cost reduction actions to improve gross margins for the overall company. As of March 28, 2025, the Company had incurred cumulative costs of $13.1 million related to the 2020 restructuring program. The 2020 restructuring program activities were completed in the fourth quarter of 2023. In January 2025, the Company sold a facility from the 2020 restructuring program and recorded a $3.6 million gain in the Company’s Automation Enabling Technologies segment.

The following table summarizes the accrual activities, by component, related to the Company’s restructuring plans recorded in the accompanying consolidated balance sheets (in thousands):


	Total			Employee Related			Facility Related			Facility Sale			Other
Balance at December 31, 2024	$	6,751		$	5,690		$	1,061		$	—		$	—
Restructuring charges		(3,005	)		(107	)		719			(4,325	)		708
Cash payments		4,444			(581	)		(147	)		5,537			(365	)
Non-cash write-offs and other adjustments		(1,679	)		162			(629	)		(1,212	)		—
Balance at March 28, 2025	$	6,511		$	5,164		$	1,004		$	—		$	343

Acquisition costs in connection with business combinations, including finders’ fees, legal, valuation, and other professional or consulting fees, totaled $0.6 million for three months ended March 28, 2025, and $1.7 million for the three months ended March 29, 2024. The majority of acquisition and related costs for the three months ended March 28, 2025 and the three months ended March 29, 2024 were included in unallocated costs.